» Articles » PMID: 16940764

Neuroprotective and Disease-modifying Effects of the Ketogenic Diet

Overview
Journal Behav Pharmacol
Date 2006 Aug 31
PMID 16940764
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

The ketogenic diet has been in clinical use for over 80 years, primarily for the symptomatic treatment of epilepsy. A recent clinical study has raised the possibility that exposure to the ketogenic diet may confer long-lasting therapeutic benefits for patients with epilepsy. Moreover, there is evidence from uncontrolled clinical trials and studies in animal models that the ketogenic diet can provide symptomatic and disease-modifying activity in a broad range of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease, and may also be protective in traumatic brain injury and stroke. These observations are supported by studies in animal models and isolated cells that show that ketone bodies, especially beta-hydroxybutyrate, confer neuroprotection against diverse types of cellular injury. This review summarizes the experimental, epidemiological and clinical evidence indicating that the ketogenic diet could have beneficial effects in a broad range of brain disorders characterized by the death of neurons. Although the mechanisms are not yet well defined, it is plausible that neuroprotection results from enhanced neuronal energy reserves, which improve the ability of neurons to resist metabolic challenges, and possibly through other actions including antioxidant and anti-inflammatory effects. As the underlying mechanisms become better understood, it will be possible to develop alternative strategies that produce similar or even improved therapeutic effects without the need for exposure to an unpalatable and unhealthy, high-fat diet.

Citing Articles

Gut Microbiome, Diet and Depression: Literature Review of Microbiological, Nutritional and Neuroscientific Aspects.

Clerici L, Bottari D, Bottari B Curr Nutr Rep. 2025; 14(1):30.

PMID: 39928205 PMC: 11811453. DOI: 10.1007/s13668-025-00619-2.


Impact of the Ketogenic Diet on Neurological Diseases: A Review.

Rubio C, Lopez-Landa A, Romo-Parra H, Rubio-Osornio M Life (Basel). 2025; 15(1).

PMID: 39860011 PMC: 11767209. DOI: 10.3390/life15010071.


DAG-MAG-ΒHB: A Novel Ketone Diester Modulates NLRP3 Inflammasome Activation in Microglial Cells in Response to Beta-Amyloid and Low Glucose AD-like Conditions.

Gentili V, Schiuma G, Dilliraj L, Beltrami S, Rizzo S, Lara D Nutrients. 2025; 17(1.

PMID: 39796582 PMC: 11722608. DOI: 10.3390/nu17010149.


Gut Microbiome Modulation of Glutamate Dynamics: Implications for Brain Health and Neurotoxicity.

Gruenbaum B, Merchant K, Zlotnik A, Boyko M Nutrients. 2025; 16(24.

PMID: 39771027 PMC: 11677762. DOI: 10.3390/nu16244405.


Neuroregeneration Improved by Sodium-D,L-Beta-Hydroxybutyrate in Primary Neuronal Cultures.

Ari C, DAgostino D, Cha B Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338322 PMC: 11435142. DOI: 10.3390/ph17091160.


References
1.
Hemingway C, Freeman J, Pillas D, Pyzik P . The ketogenic diet: a 3- to 6-year follow-up of 150 children enrolled prospectively. Pediatrics. 2001; 108(4):898-905. DOI: 10.1542/peds.108.4.898. View

2.
Stafstrom C . Dietary approaches to epilepsy treatment: old and new options on the menu. Epilepsy Curr. 2005; 4(6):215-22. PMC: 1176378. DOI: 10.1111/j.1535-7597.2004.46001.x. View

3.
Stafstrom C . Animal models of the ketogenic diet: what have we learned, what can we learn?. Epilepsy Res. 1999; 37(3):241-59. DOI: 10.1016/s0920-1211(99)00067-4. View

4.
Patel N, Gordon M, Connor K, Good R, Engelman R, Mason J . Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models. Neurobiol Aging. 2005; 26(7):995-1000. DOI: 10.1016/j.neurobiolaging.2004.09.014. View

5.
Massieu L, Haces M, Montiel T, Hernandez-Fonseca K . Acetoacetate protects hippocampal neurons against glutamate-mediated neuronal damage during glycolysis inhibition. Neuroscience. 2003; 120(2):365-78. DOI: 10.1016/s0306-4522(03)00266-5. View